Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion
Abstract Background Malignant pleural effusion (MPE) is a disease associated with poor prognosis, high morbidity, and significant mortality. Murine models of MPE have successfully replicated its formation and metastases, providing valuable insights into potential therapeutic approaches. Nanoparticle...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14622-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849764731612561408 |
|---|---|
| author | Carlos Sergio Rocha Silva Lisete Ribeiro Teixeira Karina Rocha Pereira Philippe Figueiredo Braga Colares Vanessa Adelia Alvarenga Roberta Karla Barbosa Sales Amanda Cabral Roque Evaldo Marchi Ronei Luciano Mamoni Milena Marques Pagliarelli Acencio |
| author_facet | Carlos Sergio Rocha Silva Lisete Ribeiro Teixeira Karina Rocha Pereira Philippe Figueiredo Braga Colares Vanessa Adelia Alvarenga Roberta Karla Barbosa Sales Amanda Cabral Roque Evaldo Marchi Ronei Luciano Mamoni Milena Marques Pagliarelli Acencio |
| author_sort | Carlos Sergio Rocha Silva |
| collection | DOAJ |
| description | Abstract Background Malignant pleural effusion (MPE) is a disease associated with poor prognosis, high morbidity, and significant mortality. Murine models of MPE have successfully replicated its formation and metastases, providing valuable insights into potential therapeutic approaches. Nanoparticle-associated drugs (nab) offer the advantage of reduced toxicity while enhancing their effectiveness against tumor cells. This study aims to evaluate the efficacy of intrapleural nab-Paclitaxel, either alone or in combination with anti-vascular endothelial growth factor (VEGF), in a murine model of MPE. Methods Lewis Lung Carcinoma (LLC) cells were injected intrapleurally into 300 mice. After seven days, the mice were assigned to one of five treatment groups: intrapleural administration of Paclitaxel, nab-Paclitaxel, anti-VEGF, nab-Paclitaxel + anti-VEGF, or saline (untreated). Twenty animals per group were monitored weekly for weight, mobility, and survival. Additionally, ten mice from each group were euthanized on days 7, 14, 21 and 28 to assess pleural fluid volume, cytology, lactate dehydrogenase (LDH), interleukin-6 (IL-6), VEGF, transforming necrosis factor (TNF)-α, and histological characteristics. Results Pleural carcinomatosis was lethal across all groups; however, mice receiving nab-Paclitaxel + anti-VEGF exhibited the longest survival. Pleural fluid accumulation was most pronounced in the untreated and Paclitaxel groups, whereas the lowest levels were observed in the nab-Paclitaxel + anti-VEGF group. Tumor implantation in the pleura occurred in all groups, but the lowest scores were recorded in mice treated with nab-Paclitaxel + anti-VEGF. Conclusions In this experimental MPE model, intrapleural administration of nab-Paclitaxel in combination with anti-VEGF significantly prolonged survival and reduced both pleural fluid volume and tumor implantation. |
| format | Article |
| id | doaj-art-ab8b465a180948a28a504f404cb6d4e5 |
| institution | DOAJ |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-ab8b465a180948a28a504f404cb6d4e52025-08-20T03:05:03ZengBMCBMC Cancer1471-24072025-08-0125111010.1186/s12885-025-14622-xEffect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusionCarlos Sergio Rocha Silva0Lisete Ribeiro Teixeira1Karina Rocha Pereira2Philippe Figueiredo Braga Colares3Vanessa Adelia Alvarenga4Roberta Karla Barbosa Sales5Amanda Cabral Roque6Evaldo Marchi7Ronei Luciano Mamoni8Milena Marques Pagliarelli Acencio9Pulmonary Division, Instituto do Coracao (InCor), Faculdade de Medicina, Universidade de Sao PauloPulmonary Division, Instituto do Coracao (InCor), Faculdade de Medicina, Universidade de Sao PauloPulmonary Division, Instituto do Coracao (InCor), Faculdade de Medicina, Universidade de Sao PauloPulmonary Division, Instituto do Coracao (InCor), Faculdade de Medicina, Universidade de Sao PauloPulmonary Division, Instituto do Coracao (InCor), Faculdade de Medicina, Universidade de Sao PauloPulmonary Division, Instituto do Coracao (InCor), Faculdade de Medicina, Universidade de Sao PauloPulmonary Division, Instituto do Coracao (InCor), Faculdade de Medicina, Universidade de Sao PauloMedical College of JundiaiMedical College of JundiaiPulmonary Division, Instituto do Coracao (InCor), Faculdade de Medicina, Universidade de Sao PauloAbstract Background Malignant pleural effusion (MPE) is a disease associated with poor prognosis, high morbidity, and significant mortality. Murine models of MPE have successfully replicated its formation and metastases, providing valuable insights into potential therapeutic approaches. Nanoparticle-associated drugs (nab) offer the advantage of reduced toxicity while enhancing their effectiveness against tumor cells. This study aims to evaluate the efficacy of intrapleural nab-Paclitaxel, either alone or in combination with anti-vascular endothelial growth factor (VEGF), in a murine model of MPE. Methods Lewis Lung Carcinoma (LLC) cells were injected intrapleurally into 300 mice. After seven days, the mice were assigned to one of five treatment groups: intrapleural administration of Paclitaxel, nab-Paclitaxel, anti-VEGF, nab-Paclitaxel + anti-VEGF, or saline (untreated). Twenty animals per group were monitored weekly for weight, mobility, and survival. Additionally, ten mice from each group were euthanized on days 7, 14, 21 and 28 to assess pleural fluid volume, cytology, lactate dehydrogenase (LDH), interleukin-6 (IL-6), VEGF, transforming necrosis factor (TNF)-α, and histological characteristics. Results Pleural carcinomatosis was lethal across all groups; however, mice receiving nab-Paclitaxel + anti-VEGF exhibited the longest survival. Pleural fluid accumulation was most pronounced in the untreated and Paclitaxel groups, whereas the lowest levels were observed in the nab-Paclitaxel + anti-VEGF group. Tumor implantation in the pleura occurred in all groups, but the lowest scores were recorded in mice treated with nab-Paclitaxel + anti-VEGF. Conclusions In this experimental MPE model, intrapleural administration of nab-Paclitaxel in combination with anti-VEGF significantly prolonged survival and reduced both pleural fluid volume and tumor implantation.https://doi.org/10.1186/s12885-025-14622-xMalignant pleural effusionNanoparticlesVascular endothelial growth factorExperimental model |
| spellingShingle | Carlos Sergio Rocha Silva Lisete Ribeiro Teixeira Karina Rocha Pereira Philippe Figueiredo Braga Colares Vanessa Adelia Alvarenga Roberta Karla Barbosa Sales Amanda Cabral Roque Evaldo Marchi Ronei Luciano Mamoni Milena Marques Pagliarelli Acencio Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion BMC Cancer Malignant pleural effusion Nanoparticles Vascular endothelial growth factor Experimental model |
| title | Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion |
| title_full | Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion |
| title_fullStr | Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion |
| title_full_unstemmed | Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion |
| title_short | Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion |
| title_sort | effect of intrapleural anti vascular endothelial growth factor vegf associated with nab paclitaxel in a murine model of malignant pleural effusion |
| topic | Malignant pleural effusion Nanoparticles Vascular endothelial growth factor Experimental model |
| url | https://doi.org/10.1186/s12885-025-14622-x |
| work_keys_str_mv | AT carlossergiorochasilva effectofintrapleuralantivascularendothelialgrowthfactorvegfassociatedwithnabpaclitaxelinamurinemodelofmalignantpleuraleffusion AT liseteribeiroteixeira effectofintrapleuralantivascularendothelialgrowthfactorvegfassociatedwithnabpaclitaxelinamurinemodelofmalignantpleuraleffusion AT karinarochapereira effectofintrapleuralantivascularendothelialgrowthfactorvegfassociatedwithnabpaclitaxelinamurinemodelofmalignantpleuraleffusion AT philippefigueiredobragacolares effectofintrapleuralantivascularendothelialgrowthfactorvegfassociatedwithnabpaclitaxelinamurinemodelofmalignantpleuraleffusion AT vanessaadeliaalvarenga effectofintrapleuralantivascularendothelialgrowthfactorvegfassociatedwithnabpaclitaxelinamurinemodelofmalignantpleuraleffusion AT robertakarlabarbosasales effectofintrapleuralantivascularendothelialgrowthfactorvegfassociatedwithnabpaclitaxelinamurinemodelofmalignantpleuraleffusion AT amandacabralroque effectofintrapleuralantivascularendothelialgrowthfactorvegfassociatedwithnabpaclitaxelinamurinemodelofmalignantpleuraleffusion AT evaldomarchi effectofintrapleuralantivascularendothelialgrowthfactorvegfassociatedwithnabpaclitaxelinamurinemodelofmalignantpleuraleffusion AT roneilucianomamoni effectofintrapleuralantivascularendothelialgrowthfactorvegfassociatedwithnabpaclitaxelinamurinemodelofmalignantpleuraleffusion AT milenamarquespagliarelliacencio effectofintrapleuralantivascularendothelialgrowthfactorvegfassociatedwithnabpaclitaxelinamurinemodelofmalignantpleuraleffusion |